Recall of Magellan Diagnostics' LeadCare Plus Blood Lead Test Kit
Magellan Diagnostics, Inc. is recalling its LeadCare Plus Blood Lead Test Kit due to reports of unexpectedly elevated results from certain third-party devices, which may cause false positive lead tests and unnecessary testing.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on May 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — FDA Recalls — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, cpsc, Devices) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
Recall Article: LeadCare Plus Blood Lead Test Kit
What Happened
Magellan Diagnostics, Inc. is initiating a voluntary recall of the LeadCare Plus Blood Lead Test Kit because customers reported observing unexpectedly elevated results when using certain third-party micro-collection devices for testing. This issue may lead to false positive lead results, causing delayed results and additional unnecessary testing.
Which Products Are Affected
The affected product is the LeadCare Plus Blood Lead Test Kit, Catalog Number: 82-0004, with UDI-DI: 00850355006031. This recall includes all lots and all sublots, with approximately 136 units affected. The product was distributed nationwide in the US and to countries including Argentina, Australia, and others.
What You Should Do
Consumers with the affected LeadCare Plus Blood Lead Test Kit should contact Magellan Diagnostics, Inc. for instructions, as the recall was initiated via letter. The firm's address is 101 Billerica Ave Bldg 4, North Billerica, MA 01862-1271.
Why This Matters
This recall matters because false positive results could result in unnecessary medical testing and delays in accurate diagnosis, potentially impacting patient care.
Source
This information is from the FDA recall notice, recall number Z-1894-2026. For more details, refer to the FDA website.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.